



an Open Access Journal by MDPI

## Management of Pain in Oral Mucositis

Guest Editors:

### Dr. Carlos Roldan

1. Department of Pain Medicine,  
The University of Texas MD  
Anderson Texas Center, Houston,  
TX 77030, USA

2. McGovern Medical School, The  
University of Texas Health  
Science Center at Houston  
(UTHealth), Houston, TX 77030,  
USA

### Dr. Thomas Chai

Department of Pain Medicine,  
The University of Texas MD  
Anderson Texas Center, Houston,  
TX 77030, USA

Deadline for manuscript  
submissions:

**25 January 2025**

### Message from the Guest Editors

Dear Colleagues,

Oral mucositis is a prevalent and serious side effect of cancer treatment, especially systemic chemotherapy and radiation therapy.

Symptoms of oral mucositis in radiation therapy patients usually appear after the first week, peak by the fifth week, and may persist beyond six weeks post-treatment. Current management strategies focus on preventing and repairing tissue damage and include prophylactic treatments and topical agents. Systemic medications such as non-steroidal anti-inflammatory drugs, gabapentin, and opioid analgesics are also used to aid healing and alleviate pain. Antimicrobial therapy is considered for infection prevention and treatment.

Despite these efforts, managing the pain of oral mucositis remains a challenge and a critical goal. There is a clear need for more effective treatment options that are non-invasive, safe, efficient, cost-effective, and provide sustained pain relief. This Special Issue aims to compile research from experts, exploring new therapeutic agents, strategies, and future directions for treating pain associated with oral mucositis.

Sincerely,  
Dr. Carlos Roldan  
Dr. Thomas Chai  
Guest Editors



[mdpi.com/si/212910](https://mdpi.com/si/212910)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)